Table 1.
Treatment | pD2 | Emax (%) |
---|---|---|
endo | ||
Control (Phe) | 4.48 ± 0.07 | 98.97 ± 1.31 |
60 mM KCl | 5.50 ± 4.27 | 48.99 ± 4.89∗∗∗ |
U46619 | 2.77 ± 49.53 | 13.46 ± 1.35∗∗∗ |
Propranolol | 4.84 ± 0.10∗∗∗ | 99.36 ± 0.44 |
Losartan | 6.13 ± 0.45∗∗∗ | 95.89 ± 1.98 |
Enalapril | 5.14 ± 0.08∗∗∗ | 98.67 ± 1.43 |
PD123319 | 5.21 ± 0.07∗∗∗ | 100.02 ± 0.51 |
L-NAME | 3.76 ± 1.35 | 81.48 ± 3.11∗∗∗ |
Indo | 1.40 ± 28.52 | 95.33 ± 1.47 |
Indo + L-NAME | 4.21 ± 0.26 | 91.54 ± 1.95 |
L-NAME+Arg | 4.70 ± 0.32 | 99.40 ± 0.56 |
L-NAME+ODQ | 3.54 ± 12.2 | 68.53 ± 6.77∗∗∗ |
MB | 4.33 ± 0.26 | 58.74 ± 3.31∗∗∗ |
ODQ | 4.49 ± 0.10 | 60.46 ± 7.25∗∗∗ |
Wort | 4.62 ± 0.04 | 94.11 ± 2.13∗∗ |
Akti IV | 4.75 ± 0.06∗∗ | 98.77 ± 0.50 |
BaCl2 | 5.20 ± 0.18∗ | 97.75 ± 1.09 |
Gly | 4.56 ± 0.35 | 89.34 ± 6.60∗∗ |
TEA | 4.88 ± 0.23 | 99.95 ± 1.62 |
4-AP | 4.59 ± 0.45 | 84.94 ± 1.26∗ |
-endo | ||
Control (-endo) | 3.14 ± 3.44 | 85.58 ± 3.05∗∗ |
BaCl2 | 4.36 ± 3.05 | 82.33 ± 4.93 |
Gly | 4.15 ± 1.65 | 77.48 ± 8.73 |
TEA | 4.09 ± 1.81 | 81.66 ± 4.59 |
4-AP | 3.81 ± 3.46 | 83.60 ± 7.18 |
Results were means ± SEM. ∗P < 0.05, ∗∗P < 0.01, and ∗∗∗P < 0.001 versus control (Phe) group.